»
INDUSTRY NEWS
»
Aptuit Names Jonathan Goldman as CEO
Timothy C. Tyson, Chairman of Aptuit LLC, announced the appointment of Jonathan Goldman, MD as Chief Executive Offi cer (CEO), completing the company’s senior management leadership team.
Dr. Goldman will focus his eff orts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after achieving signifi cant success at ICON Clinical Research, a leading global Contract Research Organization that specializes in the provision of clinical and other solutions that support Phase I-IV clinical studies.
Dr. Goldman stated, “I’m delighted to join Aptuit, and look forward to working closely with the entire team to leverage an outstanding value proposition that is unique in our industry. Pharma has an unmet need for lower cost, increased speed and better quality in drug discovery and development. Aptuit is the ideal partner to meet these needs across a comprehensive suite of services, supported by an approach that is both scientifi c and innovative. I look forward to continued growth of the company as the partner of choice for drug developers.”
At ICON, Dr. Goldman was most recently Executive Vice President, Global Strategic and Business Development and a member of the senior leadership team. His accomplishments included record growth levels of sales, and the development of transformative business relationships with leading pharmaceutical and biotechnology companies. Previously, his roles at ICON included Executive Vice President, Operations, Strategic Programs and Chief Medical Offi cer, ICON Medical Imaging.
3M Licenses Fentanyl Transdermal Patch Technology to STADA Arzneimittel AG
3M Drug Delivery Systems announced that STADA Arzneimittel AG has become the latest drug company to license 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
The 3M Patent (EP 2158905), which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically eff ective amount of fentanyl across the skin of a patient. The matrix device is confi gured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.
3M is open to licensing this technology to other interested parties. About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar
84 | | November/December 2013
strategy of generics and branded products (OTC) with an increasingly international market orientation.
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M’s inhalation, transdermal or microneedle drug delivery technology.
About 3M
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better.
DCAT 2013-2014 Board of Directors Take Offi ce
DCAT is pleased to announce that the slate of candidates for the 2013-2014 Board of Directors was approved by member company designated contacts. Lyra Myers, Associate Director & Value Creation Agent, Roche, now serves as president, along with the other elected board members. George Svokos, Sr. VP, Product & Portfolio Mgmt., Teva Pharmaceuticals USA, Inc., serves as senior vice president and Annual Dinner chair, and Folker Ruchatz, Sr. VP, Contract Mfg., Business Biopharmaceuticals, Boehringer Ingelheim serves as fi nance offi cer.
Former DCAT Segment Vice President-Contract Formulation, Fill, Finish, Contract Packaging Milton Boyer (president, Oso BioPharmaceuticals Manufacturing, LLC) serves as vice president of the Executive Committee.
Joining the Executive Committee are David Beattie, senior director, R&D, EMD Millipore Corp. as segment vice president biotechnology industry, Gavin Murdoch, account executive, Patheon as segment vice president contract formulation, fi ll , fi nish & contract packaging industry, and Christopher Rayfi eld, executive vice president, ACIC Fine Chemicals Inc. as segment vice president pharmaceutical services industry.
Anu Hans, vice president & enterprise supply chain CPO, Johnson & Johnson serves a second term as segment vice president- pharmaceutical industry and Paolo Magri, vice president corporate business development, Infa Inc., will serve a second term as segment vice president-chemical industry.
Former DCAT President Tyson Popp, vice president, global sourcing & Americas supply chain, West Pharmaceutical Services, joins the Executive Committee’s Advisory Council.
Completing their three-year-term on the Board of Directors were Ellen Gambichler, director, purchasing, Fougera Pharmaceuticals Inc., Michael Kopp, vice president, business development, North America, Mylan, Inc., Michael Rosenfelder, director, business development, Merck & Co., Inc., Joe Sutton, director, global API sourcing, manufacturing and R&D, Eli Lilly and Company, and Mike Velez, director, PMO, strategic initiatives lead, animal health external manufacturing and procurement.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92